CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail order, mail order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. Its Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. As of December 31, 2020, it operated approximately 9,900 retail locations and 1,100 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
IPO Year:
Exchange: NYSE
Website: cvshealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2024 | $61.00 | Neutral | Robert W. Baird |
| 5/7/2024 | $99.00 → $59.00 | Buy → Hold | TD Cowen |
| 5/2/2024 | $85.00 → $60.00 | Buy → Neutral | UBS |
| 5/1/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 5/1/2024 | $87.00 → $60.00 | Outperform → Market Perform | Leerink Partners |
| 3/6/2024 | $78.00 | Equal Weight | Barclays |
| 2/26/2024 | $88.00 | Outperform | Leerink Partners |
| 12/22/2023 | $94.00 | Buy | HSBC Securities |
| 9/19/2023 | $81.00 → $83.00 | In-line → Outperform | Evercore ISI |
| 9/12/2023 | $80.00 | Peer Perform → Outperform | Wolfe Research |
CVS pharmacists can now evaluate patients and prescribe hormonal contraceptives WOONSOCKET, R.I., Sept. 12, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced that CVS Pharmacy® locations in Massachusetts are now offering hormonal contraceptive prescribing services. Patients interested in receiving a birth control prescription can be evaluated by a CVS pharmacist and, if clinically eligible, receive a prescription for birth control. Millions of women in the United States live in contraceptive deserts1 — areas with insufficient access to birth control methods — and on
WOONSOCKET, R.I., Sept. 10, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) is actively preparing for Tropical Storm Francine, which is expected to make landfall in Louisiana as a hurricane tomorrow. The company's priority is the health and safety of its customers, members and colleagues, and it is committed to providing communities with access to the products and services they need to plan for the storm. CVS Pharmacy® is reaching out to its patients by text message, email and phone to remind them to refill and pick up prescriptions. Stores are also receiving additional supplies o
Simplified digital scheduling tool makes booking appointments even easier for families Multiple vaccinations can be administered and groups of up to four patients can be vaccinated during one visit WOONSOCKET, R.I., Aug. 28, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced that the updated 2024-2025 COVID-19 vaccines and flu vaccines are available at CVS Pharmacy® and MinuteClinic® locations nationwide. Walk-ins are being accepted at CVS Pharmacy and the company's digital vaccine scheduler has been updated to reflect available appointments at CVS Pharmacy and MinuteClinic.
WOONSOCKET, R.I., Aug. 14, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Heidi Capozzi will join the company as Executive Vice President, Chief People Officer, effective September 9. She will lead the human resources, labor relations, compensation and benefits, and corporate social responsibility teams who support CVS Health's strategy to build a world of health around every consumer. "Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and adv
AM Best has revised the outlook to stable from positive for the Long-Term Issuer Credit Rating (Long-Term ICR) and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). The outlook of the FSR is stable. (Please see below for a detailed listing of the companies.) The Credit Ratings (ratings) of Aetna Health & Life Group reflect its balance sheet strength, which AM Best assesses as very strong, as well as it
Financial Highlights Second quarter total revenues increased to $91.2 billion, up 2.6% compared to the prior yearSecond quarter GAAP diluted EPS of $1.41 and Adjusted EPS of $1.83Generated year-to-date cash flow from operations of $8.0 billion2024 Full-Year Guidance Revised GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64Revised Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00Revised cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billionCEO Commentary"We have many points of differentiation that position us to win now and into the future. Our innovation is accelerating more transparent pharmacy reimbursement
WOONSOCKET, R.I., Aug. 5, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) is prioritizing the health and safety of its customers, patients, members and colleagues as Hurricane Debby lands in Florida and travels through Georgia and the Carolinas this week. The company is committed to providing communities with access to the products and services they need amid the storm. It has implemented measures across its business to ensure continuity of care: CVS Pharmacy is reaching out to its patients by text message, email and phone to remind them to refill and pick up prescriptions. Stores
Using advanced environmental data analytics, the company powers personalized solutions to manage and protect people most at-risk from extreme weather events, including heat waves WOONSOCKET, R.I., Aug. 1, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced a first-of-its-kind environmental health impact initiative to help people most vulnerable to extreme weather events that can worsen existing chronic conditions. The initiative is focusing first on extreme heat events to provide timely excessive heat alerts and tailored outreach to at-risk patients, and will expand in
CVS Caremark pledges to accelerate transparency, drive to lowest net cost prescription drugs, strengthen pharmacy relations, and deliver the best clinical care in pharmacy WOONSOCKET, R.I., July 23, 2024 /PRNewswire/ -- CVS Caremark®, the nation's leading pharmacy benefit manager and a CVS Health® (NYSE: CVS) company, today announced a renewed pledge to American businesses, unions, and health plans — building on what the company is doing to deliver greater transparency, lower drug costs, and better clinical care for the most utilized health benefit. "The way we have done our w
WOONSOCKET, R.I., July 8, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on August 1, 2024, to holders of record on July 22, 2024. About CVS HealthCVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individu
Financial giants have made a conspicuous bullish move on CVS Health. Our analysis of options history for CVS Health (NYSE:CVS) revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $374,736, and 7 were calls, valued at $388,184. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $53.0 to $77.5 for CVS Health over the last 3 months. Analyzing Volume & Open Interest Assessing the volume and open interest is a strategic step in options trading. These metr
Across the recent three months, 15 analysts have shared their insights on CVS Health (NYSE:CVS), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 9 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 2 0 0 3M Ago 5 0 6 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.13, along with a high estimate of $86.00 and a low estimate of $58.00. Observing
Cantor Fitzgerald analyst Sarah James reiterates CVS Health (NYSE:CVS) with a Neutral and maintains $58 price target.
Financial giants have made a conspicuous bullish move on CVS Health. Our analysis of options history for CVS Health (NYSE:CVS) revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $303,820, and 7 were calls, valued at $615,689. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $70.0 for CVS Health during the past quarter. Volume & Open Interest Trends Assessing the volume and open interest is a strategic step in options trading. These metrics she
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Pfizer Inc. (NYSE:PFE) Dividend Yield: 5.81% Cantor Fitzgerald analyst Louise Chen rei
Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:CVS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for CVS Health. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 41% leaning bullish and 50% bearish. Among these notable options, 4 ar
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized. The Role Of PBMs And Market Influence PBMs, such as UnitedHealth Group (NYSE:UNH)'s Optum, CVS Health (NYSE:CVS)'s CVS Caremark and Cigna (NYSE:CI)'s Express Scripts, negotiate discounts, create medication lists covered by insurance and reimburse pharmacies. The FTC's interim report revealed that these three PBMs manage 79% of U.S. prescription drug claims, consolidating their power and impacting dru
The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating prices for drugs including insulin, after a two-year investigation into whether the companies steer patients away from less-expensive medicines.https://www.wsj.com/health/pharma/ftc-to-sue-drug-managers-over-insulin-prices-b46af71f?mod=latest_headlines
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
13F-HR - CVS HEALTH Corp (0000064803) (Filer)
10-Q - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
11-K - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
FWP - CVS HEALTH Corp (0000064803) (Subject)
424B3 - CVS HEALTH Corp (0000064803) (Filer)
13F-HR - CVS HEALTH Corp (0000064803) (Filer)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
Robert W. Baird initiated coverage of CVS Health with a rating of Neutral and set a new price target of $61.00
TD Cowen downgraded CVS Health from Buy to Hold and set a new price target of $59.00 from $99.00 previously
UBS downgraded CVS Health from Buy to Neutral and set a new price target of $60.00 from $85.00 previously
Cantor Fitzgerald downgraded CVS Health from Overweight to Neutral
Leerink Partners downgraded CVS Health from Outperform to Market Perform and set a new price target of $60.00 from $87.00 previously
Barclays initiated coverage of CVS Health with a rating of Equal Weight and set a new price target of $78.00
Leerink Partners initiated coverage of CVS Health with a rating of Outperform and set a new price target of $88.00
HSBC Securities initiated coverage of CVS Health with a rating of Buy and set a new price target of $94.00
Evercore ISI upgraded CVS Health from In-line to Outperform and set a new price target of $83.00 from $81.00 previously
Wolfe Research upgraded CVS Health from Peer Perform to Outperform and set a new price target of $80.00
AM Best has revised the outlook to stable from positive for the Long-Term Issuer Credit Rating (Long-Term ICR) and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). The outlook of the FSR is stable. (Please see below for a detailed listing of the companies.) The Credit Ratings (ratings) of Aetna Health & Life Group reflect its balance sheet strength, which AM Best assesses as very strong, as well as it
Financial Highlights Second quarter total revenues increased to $91.2 billion, up 2.6% compared to the prior yearSecond quarter GAAP diluted EPS of $1.41 and Adjusted EPS of $1.83Generated year-to-date cash flow from operations of $8.0 billion2024 Full-Year Guidance Revised GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64Revised Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00Revised cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billionCEO Commentary"We have many points of differentiation that position us to win now and into the future. Our innovation is accelerating more transparent pharmacy reimbursement
WOONSOCKET, R.I., July 8, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on August 1, 2024, to holders of record on July 22, 2024. About CVS HealthCVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individu
WOONSOCKET, R.I., July 8, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, August 7th, 2024, at 8:00 a.m. ET to discuss second quarter 2024 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including
First Quarter Highlights Total revenues increased to $88.4 billion, up 3.7% compared to prior yearGAAP diluted EPS of $0.88 and Adjusted EPS of $1.31Generated cash flow from operations of $4.9 billion2024 Full-Year Guidance Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06Revised Adjusted EPS guidance to at least $7.00 from at least $8.30Revised cash flow from operations guidance to at least $10.5 billion from at least $12.0 billionCEO Commentary"The current environment does not diminish our opportunities, enthusiasm, or the long-term earnings power of our company. We are confident we have a pathway to address our near-term Medicare Advantage challenges. We remain commi
WOONSOCKET, R.I., April 1, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, May 1st, 2024, at 8:00 a.m. ET to discuss first quarter 2024 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including mo
WOONSOCKET, R.I., March 21, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 1, 2024, to holders of record on April 22, 2024. About CVS Health CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individ
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). The outlook of the FSR is stable, while the outlook of the Long-Term ICR is positive. (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (
WOONSOCKET, R.I., Feb. 7, 2024 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) today announced operating results for the three months and year ended December 31, 2023. FOURTH QUARTER HIGHLIGHTS Total revenues increased to $93.8 billion, up 11.9% compared to prior yearGAAP diluted EPS of $1.58 and Adjusted EPS of $2.12KEY FINANCIAL DATA Three Months Ended December 31, In millions, except per share amounts 2023 2022 Change Total revenues $ 93,813 $ 83,846 $ 9,967 Operating income 3,373 3,659 (286) Adjusted operating income (1) 4,227 4,079 148 Diluted earnings per share $ 1.58 $ 1.77 $ (0.19) Adjusted EPS (2) $ 2.12 $ 2.04 $ 0.08 FULL-YEAR HIGHLIG
WOONSOCKET, R.I., Jan. 12, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, February 7, 2024, at 8:00 a.m. ET to discuss fourth quarter and full year 2023 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated
WOONSOCKET, R.I., Aug. 14, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Heidi Capozzi will join the company as Executive Vice President, Chief People Officer, effective September 9. She will lead the human resources, labor relations, compensation and benefits, and corporate social responsibility teams who support CVS Health's strategy to build a world of health around every consumer. "Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and adv
ExtraCare® is now one easy savings membership with two tiers WOONSOCKET, R.I., Jan. 4, 2024 /PRNewswire/ -- CVS Pharmacy®, the retail division of CVS Health® (NYSE:CVS), today announced the evolution of its loyalty program to include two membership tiers: ExtraCare® and ExtraCare Plus™. ExtraCare: The popular, no-fee loyalty program through which members can save hundreds of dollars1 through sale prices, email, and text personalized Deals For You, 2% back in ExtraBucks Rewards® and more, is now simpler and more valuable. ExtraCare will now include benefits previously found wit
American International Group, Inc. (NYSE:AIG) today announced that Roshan Navagamuwa will be joining AIG in December and has been named EVP and Chief Information Officer, effective January 1, 2024. Mr. Navagamuwa will report to Peter Zaffino, AIG Chairman & Chief Executive Officer, and serve on AIG's Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231114592675/en/Roshan Navagamuwa (Photo: Business Wire) As Chief Information Officer, Mr. Navagamuwa will be responsible for AIG's global technology and cybersecurity strategy, managing core infrastructure, technology partnerships and process engineering effo
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1. "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued
WOONSOCKET, R.I., July 20, 2023 /PRNewswire/ -- CVS Health® Corporation (NYSE:CVS) has appointed J. Scott Kirby, CEO of United Airlines Holdings, Inc., to serve on the Board of Directors (the "Board") of CVS Health, effective October 1. "Scott is a strategic leader adept at innovating through technology in a highly regulated, consumer driven industry," said CVS Health President and CEO Karen S. Lynch. "His insights will be a tremendous asset to our Board and will help us advance our technology-forward approach to improving consumer health." Kirby joined United Airlines as pres
Board Appointments Support the Company's Previously Announced Board Transition Plan Enhabit, Inc. (NYSE:EHAB) ("Enhabit" or the "Company"), a leading national home health and hospice provider, today announced an agreement with Cruiser Capital Advisors LLC ("Cruiser") and Harbour Point Capital Management LP ("Harbour Point" ), which collectively own approximately 4.7% of the outstanding shares of Enhabit's common stock, pursuant to which Enhabit has appointed Stuart McGuigan and Barry Schochet to its board of directors, effective immediately. With these appointments the Company's board will expand temporarily to 13 directors. As Enhabit previously disclosed in May 2022 ahead of the complet
WOONSOCKET, R.I., Oct. 6, 2022 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced it has appointed Dr. Amar Desai as President, Health Care Delivery, effective October 17. He will lead the newly formed Health Care Delivery organization, overseeing implementation of key areas of the company's health services and care delivery strategy. "This new organization will leverage the strength of the CVS Health portfolio to develop and implement payor-agnostic products and services," said CVS Health President and CEO Karen S. Lynch. "Amar's deep background in clinical delivery and v
WOONSOCKET, R.I., Sept. 13, 2022 /PRNewswire/ -- CVS Health® (NYSE:CVS) has appointed Jeffrey R. Balser, M.D., Ph.D., to serve on the Board of Directors (the "Board") of CVS Health, effective immediately. He has also been named to the Board's Medical Affairs Committee. "Dr. Balser's extensive experience in a wide range of roles across health care organizations will be an invaluable asset for the Board," said CVS Health President and CEO Karen S. Lynch. "His deep clinical expertise and leadership of a prestigious health system gives him the insight to help support our strategy
Additional funding brings Series D round to $320M totalTrevor Fetter, MBA, senior lecturer on the faculty of Harvard Business School and former longtime Tenet Healthcare chairman and CEO, named to BoardSachin H. Jain, physician executive with government, pharmaceutical, payer and provider experience, joins BoardBOSTON, Aug. 10, 2022 /PRNewswire/ -- Biofourmis, a Boston-based global leader in virtual care and digital medicine, today announced that Intel Capital, the strategic investment arm of chipmaker Intel Corporation, has joined its Series D financing in an extension that brings the total funding raised in the round to $320M. The initial Series D funding round was announced in April and w
Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006301/en/Sam Asgarian, M.D., MBA, Scipher Medicine, Chief Medical Officer (Photo: Business Wire) "We are thrilled to welcome Dr. Asgarian to our leadership team," said Alif Saleh, chief executive officer of Scipher Medicine. "His strong blend of experience as a health care clinician and business leader will serve us well as we pursue our critical mission." Dr. Asgarian joins Sci